Johnson & Johnson CEO Joaquin Duato said last week that trying to eliminate cancer “as we know it” within 10 years is a realistic target, speaking at the WSJ Leadership Institute conference in London. His remarks, reported overnight by Fox News, reflect a broader view among medical experts that cancer treatment is heading toward a major shift, with some cancers potentially becoming fully curable and others turning into chronic conditions.
Duato said the biggest advances are coming from therapies that harness the patient’s immune system to attack cancer cells. He pointed to multiple myeloma as an example, noting that a disease once measured in just a few years of survival now has a life expectancy of about a decade, and that some terminal patients have remained in complete remission for more than five years after a single treatment.
He said Johnson & Johnson’s strategy is focused on understanding the biology of tumor growth more deeply and developing new technologies to treat it. Duato also emphasized artificial intelligence, which he called a “force multiplier,” saying it is helping speed up both drug development and diagnosis. He added that combining genetic insight with advanced tools allows for more personalized treatment for each patient.
Medical analyst Dr. Marc Siegel backed that outlook, saying AI helps detect disease earlier and plan more precise, individualized surgeries. He also noted that Johnson & Johnson recently bought the biotech company Firefly Bio, which develops drugs that enter cancer cells and neutralize mutated proteins that are difficult to treat with conventional methods. Beyond cancer, Duato said dementia is likely to be one of the next major social challenges requiring scientific solutions, and he expressed optimism that longevity technologies will continue improving while also enhancing quality of life.
